| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $57,781 | 2 | 67 |
Sells | $110,547 | 1 | 33 |
| WEAVER GREGORY L | Chief Financial Officer | 1 | $51,996 | 0 | $0 | $51,996 |
| Sohn Catherine A. | director | 1 | $5,785 | 0 | $0 | $5,785 |
| Drutz David | director | 0 | $0 | 1 | $110,547 | $-110,547 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Over the last 12 months, insiders at Altimmune, Inc. have bought $57,781 and sold $110,547 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $43,959 and sold $658,271 worth of stock each year.
Highest buying activity among insiders over the last 12 months: WEAVER GREGORY L (Chief Financial Officer) — $51,996. Sohn Catherine A. (director) — $5,785.
The last purchase of 1,000 shares for transaction amount of $5,785 was made by Sohn Catherine A. (director) on 2025‑03‑17.
| 2025-03-17 | Sohn Catherine A. | director | 1,000 0.0013% | $5.78 | $5,785 | -8.02% | ||
| 2025-03-13 | WEAVER GREGORY L | Chief Financial Officer | 10,000 0.013% | $5.20 | $51,996 | +5.99% | ||
| 2024-08-19 | Sale | Drutz David | director | 16,011 0.0206% | $6.90 | $110,547 | -12.33% | |
| 2023-08-15 | Drutz David | director | 300 0.0006% | $2.88 | $863 | +145.20% | ||
| 2023-03-24 | Eisenstadt Richard I | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | ||
| 2023-03-23 | Harris Matthew Scott | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | ||
| 2023-03-23 | Drutz David | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | ||
| 2022-12-22 | Sale | Pisano Wayne | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | |
| 2022-08-30 | Sale | Garg Vipin K | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% | |
| 2022-08-12 | Sale | Garg Vipin K | President and CEO | 15,000 0.0264% | $15.06 | $225,890 | -39.92% | |
| 2022-08-12 | Sale | GILL JOHN | director | 2,714 0.0048% | $15.00 | $40,710 | -39.92% | |
| 2022-07-01 | Sale | Roberts M Scot | Chief Scientific Officer | 10,182 0.022% | $12.00 | $122,184 | +0.62% | |
| 2022-06-29 | Sale | Roberts M Scot | Chief Scientific Officer | 5,462 0.0117% | $12.00 | $65,546 | -3.74% | |
| 2022-06-27 | Sale | Roberts M Scot | Chief Scientific Officer | 37,352 0.0803% | $12.00 | $448,254 | -3.40% | |
| 2022-06-27 | Sale | Jorkasky Diane | 17,610 0.0371% | $11.75 | $206,944 | -3.40% | ||
| 2022-06-15 | Drutz David | 1,000 0.002% | $8.00 | $8,000 | +36.66% | |||
| 2022-05-24 | Drutz David | 1,200 0.0024% | $4.50 | $5,400 | +140.89% | |||
| 2022-02-28 | Sale | Harris Matthew Scott | Chief Medical Officer | 30,000 0.0692% | $7.52 | $225,600 | +52.50% | |
| 2021-03-01 | Sale | Hodges Philip | director | 6,000 0.0151% | $16.08 | $96,480 | -28.09% | |
| 2020-12-10 | Schafer Klaus | director | 2,000 0.0076% | $11.99 | $23,980 | +5.50% |
| Drutz David | director | 41958 0.0517% | $290,349.36 | 6 | 1 | +43.65% |
| WEAVER GREGORY L | Chief Financial Officer | 10000 0.0123% | $69,200.00 | 1 | 0 | |
| Sohn Catherine A. | director | 1000 0.0012% | $6,920.00 | 1 | 0 | |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 8.17% | $45.85M | 1 | 3 | |
| EVNIN LUKE | 10 percent owner | 6347614 7.8262% | $43.93M | 2 | 0 | |
| MPM BIOVENTURES III LLC | 10 percent owner | 6347614 7.8262% | $43.93M | 2 | 0 | |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 5.5482% | $31.14M | 4 | 0 | +64.5% |
| VELOCITY PHARMACEUTICAL HOLDINGS LLC | 10 percent owner | 1687250 2.0803% | $11.68M | 0 | 2 | |
| SCHAFFER DERACE L | director | 589453 0.7268% | $4.08M | 41 | 5 | <0.0001% |
| KINLEY MATTHEW P | 541000 0.667% | $3.74M | 11 | 0 | ||
| WRIGHT DAVID P | President and CEO | 399500 0.4926% | $2.76M | 8 | 0 | |
| PAPPAJOHN JOHN | director | 394044 0.4858% | $2.73M | 15 | 3 | |
| Enright William | President and CEO | 365839 0.4511% | $2.53M | 1 | 0 | <0.0001% |
| HEALTHCARE VENTURES VII LP | 10 percent owner | 250000 0.3082% | $1.73M | 1 | 0 | |
| Garg Vipin K | President and CEO | 236797 0.292% | $1.64M | 1 | 2 | |
| RICHMAN ERIC I | director | 176822 0.218% | $1.22M | 2 | 3 | |
| Riddle Valerie D | SVP, Medical Director | 44436 0.0548% | $307,497.12 | 0 | 3 | |
| Harris Matthew Scott | Chief Medical Officer | 33311 0.0411% | $230,512.12 | 1 | 2 | <0.0001% |
| SAYARE MITCHEL | director | 32650 0.0403% | $225,938.00 | 2 | 0 | <0.0001% |
| CHANG LINDA L | SVP, CFO & Secretary | 30000 0.037% | $207,600.00 | 1 | 1 | |
| St Peter Steven | director | 25000 0.0308% | $173,000.00 | 1 | 0 | |
| Eisenstadt Richard I | Chief Financial Officer | 22010 0.0271% | $152,309.20 | 1 | 0 | <0.0001% |
| Runge Jeffrey W. | director | 20000 0.0247% | $138,400.00 | 2 | 0 | |
| FUERST THOMAS RICHARD | SVP, Chief Scientific Officer | 15000 0.0185% | $103,800.00 | 2 | 0 | |
| Karp Jordan P | SVP, General Counsel | 10000 0.0123% | $69,200.00 | 1 | 0 | |
| Schafer Klaus | director | 8900 0.011% | $61,588.00 | 1 | 1 | +5.5% |
| Hodges Philip | director | 8731 0.0108% | $60,418.52 | 0 | 3 | |
| Pisano Wayne | director | 8498 0.0105% | $58,806.16 | 1 | 2 | <0.0001% |
| Roberts M Scot | Chief Scientific Officer | 8305 0.0102% | $57,470.60 | 1 | 3 | <0.0001% |
| GILL JOHN | director | 2771 0.0034% | $19,175.32 | 1 | 2 | <0.0001% |
| Price Kevin | President-Pharmathene UK, Ltd. | 2500 0.0031% | $17,300.00 | 1 | 0 | |
| Jorkasky Diane | 0 0% | $0 | 0 | 1 |
$47,282,828 | 47 | -17.38% | $561.42M | |
Altimmune, Inc. (ALT) | $24,384,691 | 42 | -30.27% | $561.26M |
$28,907,358 | 35 | 41.41% | $654.06M | |
$94,912,877 | 34 | -7.15% | $644.31M | |
$16,271,606 | 27 | 24.11% | $538.44M | |
$111,056,143 | 19 | -7.49% | $621.37M | |
$22,007,592 | 17 | -0.43% | $586.92M | |
$152,858,569 | 14 | -4.66% | $549.12M | |
$18,945,106 | 14 | -27.94% | $664.29M | |
$133,809,976 | 13 | 31.29% | $539.41M | |
$92,357,691 | 12 | 87.24% | $550.74M | |
$94,976,497 | 10 | -10.72% | $629.5M | |
$11,541,901 | 10 | 8.07% | $557.54M | |
$91,721,700 | 9 | -13.73% | $579.22M | |
$1,580,951 | 9 | -14.18% | $554.67M | |
$73,280,625 | 6 | -41.09% | $553.73M | |
$18,704,399 | 5 | -20.93% | $584.19M | |
$3,200,000 | 5 | -11.36% | $552.05M | |
$504,640 | 1 | 16.84% | $534.86M |
| Increased Positions | 80 | +37.91% | 6M | +14.31% |
| Decreased Positions | 84 | -39.81% | 8M | -19.86% |
| New Positions | 26 | New | 1M | New |
| Sold Out Positions | 30 | Sold Out | 2M | Sold Out |
| Total Postitions | 207 | -1.9% | 38M | -5.55% |
| Blackrock, Inc. | $35,400.00 | 7.97% | 6.14M | -24,075 | -0.39% | 2025-03-31 |
| Ameriprise Financial Inc | $30,321.00 | 6.83% | 5.25M | +1M | +35.57% | 2024-12-31 |
| Vanguard Group Inc | $25,570.00 | 5.76% | 4.43M | -552,246 | -11.08% | 2024-12-31 |
| State Street Corp | $20,022.00 | 4.51% | 3.47M | +56,190 | +1.65% | 2024-12-31 |
| Tang Capital Management Llc | $15,868.00 | 3.57% | 2.75M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $9,570.00 | 2.15% | 1.66M | -9,498 | -0.57% | 2024-12-31 |
| Knoll Capital Management, Llc | $6,471.00 | 1.46% | 1.12M | 0 | 0% | 2024-12-31 |
| Bellevue Group Ag | $5,455.00 | 1.23% | 945,446 | +81,786 | +9.47% | 2024-12-31 |
| Morgan Stanley | $5,319.00 | 1.2% | 921,822 | -373,763 | -28.85% | 2024-12-31 |
| Ubs Group Ag | $4,152.00 | 0.93% | 719,555 | +437,100 | +154.75% | 2024-12-31 |